ELEV 0.60 Elevation Oncology, Inc.
| Range: | 0.363-5.83 | Vol Avg: | 1130764 | Last Div: | 0 | Changes: | 0.02 |
| Beta: | 1.24 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jun 25 2021 | Empoloyees: | 29 | ||
| CUSIP: | 28623U101 | CIK: | 0001783032 | ISIN: | US28623U1016 | Country: | US |
| CEO: | Mr. Joseph J. Ferra Jr. | Website: | https://elevationoncology.com | ||||
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Stock Details
Positive 0.39
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
Elevation Oncology (ELEV) might move higher on growing optimism about its earnings prospec...
zacks.com·Thu Oct 10 2024
Positive 0.23
Empery Asset Management's Strategic Acquisition in Elevation Oncology
On September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) made a significant ...
gurufocus.com·Wed Oct 09 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow